Test Price
2,800 AED✅ Home Collection Available
MYH3 Gene Distal Arthrogryposis Type 2A Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing (NGS) processing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
- Clinical Guidance: Post-test telephonic consultation with a consultant medical geneticist for result interpretation and multidisciplinary care coordination.
- Insurance: Direct billing verification available via WhatsApp at +971 54 548 8731.
This definitive molecular diagnostic examination confirms the genetic etiology of distal arthrogryposis type 2A (DA2A) and enables targeted management planning under UAE healthcare standards.
Test Overview & Methodology
This advanced NGS test sequences the entire coding region of the MYH3 gene, including intron-exon boundaries, to detect single-nucleotide variants (SNVs), small insertions and deletions (indels), and copy-number variations (CNVs) associated with distal arthrogryposis type 2A (Freeman-Sheldon syndrome). In the UAE, this examination serves as the gold-standard molecular tool for confirming clinical suspicion of DA2A, which presents with congenital joint contractures of the hands and feet, characteristic facial features (small mouth, pursed lips, deep nasolabial folds), and variable severity. The test is conducted at DNA Labs UAE, a DHA-licensed facility (License No. 1143) located in Dubai Healthcare City.
| Feature | Our NGS Test (MYH3) | Sanger Sequencing (Alternative) |
|---|---|---|
| Coverage | Full coding region + intron-exon boundaries | Single exon targeted |
| Variant Detection | SNVs, indels, CNVs with high depth | Only SNVs and small indels |
| Turnaround Time | 3-4 Weeks | 4-6 Weeks |
| Regulatory Compliance | DHA-MOHAP NGS Guidelines, ISO 9001:2015 | Legacy CLIA (non-DHA specific) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I recognize the emotional weight that accompanies a genetic diagnosis. This NGS test, when integrated with a thorough clinical evaluation and family history, delivers a definitive molecular diagnosis for distal arthrogryposis type 2A, empowering clinicians to provide targeted interventions and informed family planning. Genetic results must always be interpreted in the context of a specialist’s comprehensive assessment.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
Do not discontinue any prescribed medication or alter your treatment plan solely on the basis of genetic test results. Always consult your treating physician before making any changes to your care regimen.
Exclusion Criteria & Emergency Red Flags
- This test is not indicated for acute medical emergencies or for screening asymptomatic individuals without a clinical suspicion of DA2A.
- Pregnant patients considering prenatal diagnosis must undergo separate genetic counselling prior to sample collection.
- Emergency Red Flags: Seek immediate emergency care if you or your child experience sudden worsening of joint contractures, respiratory distress, or feeding difficulties.
Patient FAQ & Clinical Guidance
1. What is the MYH3 Gene Distal Arthrogryposis Type 2A Genetic Test used for?
This advanced genetic test detects pathogenic mutations in the MYH3 gene to confirm a diagnosis of distal arthrogryposis type 2A (Freeman-Sheldon syndrome), providing essential clarity for joint contractures, facial dysmorphism, and associated clinical features.
2. How is the test performed and what sample is required?
A trained mobile phlebotomist collects a peripheral whole blood sample, extracted DNA, or a single drop of blood on an FTA card during a convenient home visit across all UAE emirates. The sample is transported under temperature-controlled cold-chain conditions to our ISO-accredited laboratory.
3. What do the results mean and how long does it take to receive them?
Results are interpreted by a consultant medical geneticist to confirm or exclude DA2A and to guide multidisciplinary management. The standard turnaround time from sample receipt is 3 to 4 weeks.
UAE Regulatory & Data Privacy Adherence
DHA-Licensed Facility (License No. 1143) located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab Branding: DNA Labs UAE. Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 certified.
Clinical & Logistical Metadata
| Test Name | MYH3 Gene Distal Arthrogryposis Type 2A Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Coding Region Analysis Including Intron-Exon Boundaries |
| ICD-10-CM Code | Q74.3 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians